Navigation Links
Astellas Joins the National Pharmaceutical Council
Date:5/14/2013

WASHINGTON, May 14, 2013 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Astellas Scientific and Medical Affairs, Inc. (Astellas), a U.S. affiliate of Tokyo-based Astellas Pharma Inc., has joined the health policy research organization as its newest member.  

Located in Northbrook, Illinois, Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Jeffrey Bloss , M.D., vice president, scientific and medical affairs, will be the company's representative on the NPC board of directors.

"We welcome Dr. Bloss to our board of directors and are looking forward to Astellas' participation in NPC's activities," said NPC President Dan Leonard . "Their perspective will be an invaluable resource for NPC as we continue our mission to educate decision-makers about the tremendous value that the biopharmaceutical industry adds to the health and well-being of Americans."

NPC is actively engaged in conducting health care policy research on topics such as the challenges of individual patient treatment effects, the utilization of real-world evidence and comparative effectiveness research, and understanding the role and value of pharmaceuticals within the current and evolving payment and delivery models.

"We are at an important time of great change with a new health care law, the increasing individualization of drug treatments, and a change in the conversation about those treatments. I look forward to working with NPC as it meets these challenges," said Dr. Bloss. "The biopharmaceutical industry has such an important story to tell, so it is a critical time to be involved with NPC."

About the National Pharmaceutical Council:

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United Sates that supports medical innovation.  Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients.  For more information visit www.npcnow.org and follow NPC on Twitter @npcnow.


'/>"/>
SOURCE National Pharmaceutical Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Gift of Hope Organ & Tissue Donor Network Join Forces to Raise Awareness of Need for More Organ Donors in Illinois
2. Astellas and Gift of Hope Organ & Tissue Donor Network Join Forces to Raise Awareness of Need for More Organ Donors in Chicago
3. Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
4. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
5. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
6. Astellas to Drive PGA TOURs New Womens Initiative
7. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
10. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
11. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
Breaking Medicine News(10 mins):